Just 1 in 3 U.S. adults with hepatitis C have been cured between 2013 and 2022, according to a new Centers for Disease Control and Prevention report, despite the availability of highly effective antivirals. The report also found that: — People without health insurance were the least likely to be cured. — People age 60 and over on Medicare or private insurance had the highest cure rate, but less than half of them had been cured. — Just 1 in 4 people under the age of 40 were cured. Why it matters: More than 2 million people nationwide have hepatitis C, a liver infection often spread by intravenous drug use. It can be fatal and kills more than 15,000 people annually. What’s the problem? The treatments can be prohibitively expensive — some can cost close to $100,000. Many insurance plans restrict access. It can be particularly difficult for incarcerated people to get treatment because state policies for treatment in prison vary, as STAT has reported. Hepatitis C rates are exponentially higher in prisons than in the rest of the population. What’s next? Former National Institutes of Health Director Francis Collins has pushed a hepatitis C test-and-treat plan that the Biden administration has requested $12 billion for in fiscal 2024. Collins told Ben it was lamentable to have an “incredibly effective therapeutic” and not be able to administer it. “That doesn't feel like what a country that cares about all its citizens would be doing," he said. A senior GOP aide previously told POLITICO there is deep skepticism in his party about the price tag, even though the Biden administration contends the Collins plan could produce $5 billion in savings over 10 years by reducing health care costs. Collins told POLITICO that he hopes the Congressional Budget Office will confirm that, making it easier to convince lawmakers to go along.
|